Both isoforms were present in prostate adenocarcinoma, but canonical MED19 expression was more prominent (histoscore 4 + 3 for canonical MED19 and 3 + 2 for alternative MED19) (Fig. 2A; bottom panels). Here, MED19 is linked to prostate adenocarcinoma.